BG112166A - Anti asthmatic medicine - Google Patents

Abstract

Bronchial asthma is a neuroendocrine disease. The development of the disease process has two stages: a) first stage - neuroendocrine; b) second stage - allergic. It is a consequence of the changes in the neuroendocrine status of the organism during the first stage. There is allergy in patients with asthma, not allergic asthma. The modern asthmatologists treat allergy, not asthma, i.e. treating the result, not the cause. The bronchial asthma has two clinical forms: a) central / sympathetic / asthma. The causes / stress, viral infections, immunizations, vaccinations, etc. / act on the structures of the central nervous system and increase the tone of the sympathetic part of the vegetative nervous system. A blocker of the sympathetic tone is ergotaminum tartaricum. b) peripheral nerve asthma or asthmatic bronchitis. The causes / bacterial infections, radiation, irritants from acetone, ammonia, etc.) act on the soft tissues of the bronchial tree and increase the tone of the parasympathetic nucleus of the vagus nerve - the endocrine glands produce a thick and sticky secretion that clogs the bronchi. A blocker of the parasympathetic is the atropine. The alternative treatment of bronchial asthma lasts about a year. For the next 20-30 years and more, the patient is healthy and efficient. 1 claim

Description

(54) ANTIASTHMATIC MEDICINE (57) Bronchial asthma is a neuroendocrine disease. The development of the disease process has two stages.

a / first stage - neuroendocrine b / second stage - allergic. It is a consequence of changes in the neuroendocrine status of the body in the first stage. There is an allergy to asthma, not an allergic asthma disease.

Modern asthmatologists treat allergies, not asthma, ie. treat the consequence, not the cause.

Bronchial asthma has two clinical forms.

a / central / sympathetic / asthma.

The causes / stress, viral infections, immunizations, vaccinations, etc. act on the structures of the central nervous system and increase the tone of the sympathetic part of the autonomic nervous system. A blocker of increased sympathetic tone is ergotamine tartaricum.

b / peripheral nervous asthma or asthmatic bronchitis. Causes / bacterial infections, radiation, irritating fumes from acetone, ammonia, etc.! act on the soft tissues of the bronchial tree and increase the tone of the parasympathetic nucleus of the vagus nerve - the endocrine glands produce a thick and sticky secretion that clogs the bronchi. The parasympathetic blocker is atropine.

Alternative treatment for bronchial asthma lasts about a year. For the next 20-30 years and more, the patient is healthy and able to work.

claim

Description of the invention of an antiasthmatic drug

Antiasthmatic drug

The invention relates to an anti-asthmatic drug containing the following compounds in mg:

atropine sulfate from 0.50 to 2.50; papaverine hydrochloride from 50.00 to 250.00; pure caffeine from 40.00 to 260.00; ergotamine tartrate from 0.50 to 2.50; zinc sulphate from 20.00 to 430.00; Clenbuterol from 50.00 to 150.00; theophylline from 50.00 to 250.00; ergomet from 50.00 to 550.00

FIELD OF THE INVENTION

The invention relates to an anti-asthmatic drug for use in human medicine for the treatment of bronchial asthma and asthmatic bronchitis.

BACKGROUND OF THE INVENTION

A number of drugs are known for the treatment of bronchial asthma and asthmatic bronchitis.

Xanthines are known for their stimulating effect on respiration and relief of bronchospasm / Martindale 1989 /. Their combinations with other drugs are also known, which show mainly preventive and prophylactic action / BE 903065 /.

Atropine sulfate is known as an antimuscarinic agent and its use in asthma / Paterson J.W. and Tarala R.A., Med. J. Aust., 1985,143, 390 /.

Papaverine hydrochloride is known as an indisputable antispasmodic. It eliminates bronchial spasms and calms the breathing center of the cough / Martingale, 1989 /.

Ergotamine is known as a sympatholytic (Martingale, 1989) and its specific effect in congestive lung conditions, which is probably due to its vasoconstrictive effect on bronchial vessels.

All these drugs affect moments of the symptoms of the disease without interrupting its development.

Corticosteroids are known as drugs used to treat bronchial asthma and spasmodic bronchitis (Martingale, 1989). Their disadvantages are that they can lead to manifestations of drug hypercorticism - obesity, hypertension, osteoporosis, gastric and duodenal ulcers, infections and others. After starting treatment, the patient becomes completely dependent on exogenous corticosteroids, and although his condition improves to some extent, new seizures are not prevented.

Patent Asthma 2015

Page 1 of 5

Description of the invention of an antiasthmatic drug

The problem is to create an anti-asthmatic drug that stops the attacks of the disease and leads to prolonged remission for years, ie. to a practical cure, while not showing the severe side effects of corticosteroids.

SUMMARY OF THE INVENTION

The problem is solved by creating an anti-asthmatic drug that contains atropine sulfate, papaverine hydrochloride, caffeine, ergotamintartarram, zinc sulfate, novfillin and clemagetin in the following quantitative ratios in mg:

atropine sulfate from 0.50 to 2.50; papaverine hydrochloride from 50.00 to 250.00; pure caffeine from 40.00 to 260.00; ergotamine tartrate from 0.50 to 2.50; zinc sulphate from 20.00 to 430.00; Clenbuterol from 50.00 to 150.00; theophylline from 50.00 to 250.00; ergomet from 50.00 to 550.00

The combination of active substances according to the invention is suitable for the preparation of pharmaceutical forms using the excipients and carriers customary in pharmaceutical technology. The advantages of the means according to the invention are the following:

1. Control asthma attacks in 10-15 minutes

2. Prevents recurrence of painful asthmatic breathing and subsequent asthma attacks for a period of 40 years or more, while having good tolerability and does not show severe side effects and complications of corticosteroids.

Examples of the invention.

The following examples illustrate the invention without limiting it.

Example 1: the agent contains in mg:

atropine sulfate of 0.50;

papaverine hydrochloride of 50.00;

pure caffeine of 40.00;

ergotamine tartrate of 0.50;

zinc sulphate from 30.00;

Clenbuterol from 50.00;

theophylline 100.00;

ergomet of 100.00.

Patent Asthma 2015

Page 2 of 5

Description of the invention of an antiasthmatic drug

Example 2: the agent contains in mg: atropine sulfate of 2.50;

papaverine hydrochloride of 250.00;

pure caffeine of 100.00;

ergotamine tartrate of 2.50;

zinc sulphate of 430.00;

Clenbuterol from 150.00;

theophylline 200.00;

ergomet of 500.00.

Example 3: the agent contains in mg: atropine sulfate of 0.50;

papaverine hydrochloride of 50.00;

pure caffeine of 40.00;

ergotamine tartrate of 0.50;

zinc sulphate of 430.00;

Clenbuterol from 150.00;

theophylline 100.00;

ergomet of 500.00.

Example 4: the agent contains in mg: atropine sulfate of 2.50;

papaverine hydrochloride of 250.00;

pure caffeine of 100.00;

ergotamine tartrate of 2.50;

Patent Asthma 2015

Page 3 of 5

A description of the invention of an angiostatic drug zinc sulphate of 420.00;

Clenbuterol from 100.00;

theophylline 250.00;

ergomet of 500.00.

Example 5:

The treatment scheme for patients with bronchial asthma or asthmatic bronchitis with a medicament according to the invention.

The drug according to Example 1 was administered in the form of dragees. The first 30 days are given four times a day, at least every 4 hours for 1 / one / tablet. For the next 60 / sixty / days the drug is given three times a day, at 6 / six / hours. The next 60 / sixty / days the drug is given twice a day, at 12 o'clock. For the next 60 / sixty / days the drug is given once a day, only the night before bedtime.

The agent according to the invention has been tested on 300 patients with bronchial asthma and chronic asthmatic bronchitis. All patients improved after the first 15-20 minutes after taking the pill. In the observed patients it was found that there are no side effects and complications inherent in corticosteroids. The treatment is permanent and no recurrences are observed.

The results confirm the conclusion that the individual components of the combination according to the invention, in addition to having an additive effect, mutually enhance the effect on the bronchi, which has been proven in numerous clinical trials.

Patent Asthma 2015

Page 4 of 5

Description of the invention of an antiasthmatic drug

Claims (1)

The antiasthmatic drug, characterized in that it contains atropine sulfate, papaverine hydrochloride, pure caffeine, ergotamine tartrate, zinc sulfate, Clenbuterol, theophylline, ergomet in the following quantitative ratios in mg: atropine sulfate from 0.50 to 2.50; papaverine hydrochloride from 50.00 to 250.00; pure caffeine from 40.00 to 260.00; ergotamine tartrate from 0.50 to 2.50; zinc sulphate from 20.00 to 430.00; Clenbuterol from 50.00 to 150.00; theophylline from 50.00 to 250.00; ergomet from 50.00 to 550.00 Patent Asthma 2015